- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03613246
NVT ALLEGRA TAVI System TF in Failing Calcified Aortic Heart Valves in a Real-world Patient Population (FOLLOW)
March 22, 2023 updated by: NVT GmbH
Clinical Outcomes of the NVT ALLEGRA TAVI System TF in Failing Calcified Aortic Heart Valves in a Real-world Patient Population With Elevated Surgical Risk
The study collects real-world data of patients who were treated with the ALLEGRA TAVI System TF and evaluates early and midterm clinical and quality of life outcome.
Study Overview
Status
Recruiting
Conditions
Study Type
Observational
Enrollment (Anticipated)
200
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Oulu, Finland, 90220
- Recruiting
- Oulu University Hospital
-
-
-
-
-
Bad Bevensen, Germany, 29549
- Recruiting
- Herz- und Gefässzentrum Bad Bevensen
-
Hamburg, Germany, 22087
- Terminated
- Kath. Marienkrankenhaus
-
Hannover, Germany, 30625
- Recruiting
- MH Hannover
-
Heilbronn, Germany, 74078
- Active, not recruiting
- SLK-Kliniken Heilbronn
-
-
-
-
-
Milan, Italy, 20132
- Active, not recruiting
- Ospedale San Raffaele
-
-
-
-
-
Eindhoven, Netherlands, 5623 EJ
- Recruiting
- Heartcentre Catharina Hospital Eindhoven
-
-
-
-
-
Madrid, Spain, 28046
- Recruiting
- Hospital Universitario La Paz
-
Málaga, Spain, 29010
- Recruiting
- Hospital Universitario Virgen de la Victoria
-
Salamanca, Spain, 37007
- Recruiting
- Hospital Universitario de Salamanca
-
Vigo, Spain, 36213
- Recruiting
- Hospital Álvaro Cunqueiro
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Symptomatic patients with elevated surgical risk and candidate for TAVI with severe calcified and stenotic aortic valves or failing surgical bioprosthetic aortic valves.
Description
Inclusion Criteria:
- Symptomatic degeneration of severe calcified aortic heart valve OR failing surgical aortic bioprosthetic valve
- Acceptable candidate for elective treatment with the ALLEGRA TAVI System TF (according to the most recent version of the ALLEGRA Instructions For Use)
- High risk for surgery as assessed by the heart team
- Has signed the Patient Informed Consent Form >= 18 years
Exclusion Criteria:
General:
- Echocardiographic evidence of intracardiac thrombus or vegetation
- Significant aortic disease such as severe obstructive calcification or marked tortuosity or kinking which will preclude a safe advancement of the ALLEGRA TAVI System TF
- Iliofemoral vessel conditions such as severe obstructive calcification, severe tortuosity or kinking that would preclude safe placement of an 18 Fr introducer sheath or make endovascular access to the aortic valve impossible
- Severe ventricular dysfunction with LVEF <20%
- Evidence of active endocarditis or other acute infections
- Renal failure requiring continuous renal replacement therapy
- Known hypersensitivity to contrast media, which cannot be adequately pre-medicated or contraindication to anticoagulant or anti-platelet medication or to nitinol alloy or to bovine tissue
- Life expectancy ≤ 12 months due to other medical illness
- Currently participating in another investigational drug or device study
Patients with native aortic valve disease:
- Unicuspid or bicuspid aortic valve
- Non-calcified aortic stenosis
- Combined aortic valve disease with predominant aortic regurgitation > 3
- Distance between aortic valve basal plane and the orifice of the lowest coronary artery < 8 mm
Patients with degenerated surgical bioprosthetic aortic valves:
- Low position of the coronary ostia, especially in combination with shallow sinuses
- Internal diameter of the bioprosthesis is ≤16 mm or >28 mm
- Partially detached leaflets that in the aortic position may obstruct a coronary ostium
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cardiovascular death
Time Frame: 30 days post-index procedure
|
30 days post-index procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
All-cause mortality
Time Frame: up to two years
|
up to two years
|
|
Technical success of implantation
Time Frame: day of procedure
|
Technical success of implantation, as defined by:
|
day of procedure
|
Assesment of NYHA classification
Time Frame: 30 days, 12 month, 24 month
|
30 days, 12 month, 24 month
|
|
Safety profile according to VARC II
Time Frame: 30 days
|
Early Safety
Time-related valve safety
|
30 days
|
In-hospital mortality
Time Frame: date of procedure till date of estimated discharge, assessed up to two weeks
|
date of procedure till date of estimated discharge, assessed up to two weeks
|
|
Quality of life (EQ5D 5L)
Time Frame: 30 days, 12 month, 24 month
|
30 days, 12 month, 24 month
|
|
New pacemaker implantation
Time Frame: up to two years
|
up to two years
|
|
assessment of mean aortic gradient post-implantation
Time Frame: up to two years
|
up to two years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 20, 2019
Primary Completion (Anticipated)
December 1, 2024
Study Completion (Anticipated)
February 1, 2025
Study Registration Dates
First Submitted
July 6, 2018
First Submitted That Met QC Criteria
July 27, 2018
First Posted (Actual)
August 3, 2018
Study Record Updates
Last Update Posted (Actual)
March 23, 2023
Last Update Submitted That Met QC Criteria
March 22, 2023
Last Verified
April 1, 2022
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- NVT04FOL
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Transcatheter Aortic Valve Implantation
-
Aarhus University Hospital SkejbyOdense University Hospital; Aalborg University HospitalRecruitingTranscatheter Aortic Valve ImplantationDenmark
-
French Cardiology SocietyRecruitingTranscatheter Aortic Valve ImplantationFrance
-
Henry Ford Health SystemHenry Ford HospitalCompletedTranscatheter Aortic Valve ImplantationUnited States
-
NVT GmbHCompletedTranscatheter Aortic Valve ImplantationGermany
-
Cardiapex Ltd.TerminatedTransapical Transcatheter Aortic Valve ImplantationGermany
-
Dr. Giuseppe MusumeciNot yet recruitingTransfemoral tranScatheter Aortic valvE ImplantationItaly
-
Tel-Aviv Sourasky Medical CenterUnknownTranscatheter Aortic Valve Implantation Prosnosis and ComplicationsIsrael
-
Duk-Woo Park, MDBoston Scientific Corporation; CardioVascular Research Foundation, KoreaRecruitingAortic Valve Disease | Transcatheter Aortic Valve Replacement | Transcatheter Aortic Valve ImplantationKorea, Republic of
-
Rabin Medical CenterRecruitingPROM | Transcatheter Aortic Valve Implantation | Patient Reported OutcomesIsrael
-
University Hospital, EssenCompletedTransaortic Transcatheter Aortic Valve ImplantationGermany